<DOC>
	<DOCNO>NCT01242579</DOCNO>
	<brief_summary>The purpose study ass pharmacokinetics combination dapivirine maraviroc gel determine whether safe daily use healthy woman United Kingdom</brief_summary>
	<brief_title>A Safety Pharmacokinetic Study Dapivirine Maraviroc Gel Belgium</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>Women 18 to40 year age give write informed consent ( illiterate participant may provide thumbprint mark witness sign person independent trial staff ) ; Available visit consent follow procedure schedule trial ; HIVnegative determine HIV test time enrollment ; Be stable form contraception , define : A stable oral contraceptive regimen least 2 month prior enrollment , OR , Transdermal contraceptive patch least 3 month prior enrollment , OR , Longacting progestin least 6 month prior enrollment , OR , An IUD insert ( vaginal gynaecological complaint associate use ) least 3 month prior enrolment , OR , Have undergone surgical sterilization least 3 month prior enrollment ; In absence use exogenous hormone ( ) , selfreported regular menstrual cycle , define minimum 21 day maximum 35 day menses ; Upon pelvic examination colposcopy time enrollment , cervix vagina appear normal determined Investigator ; Asymptomatic genital infection time enrollment ( woman diagnose treatable STI , either syndromically laboratory test time screening , must receive treatment least 2 week prior enrollment complete treatment ) ; Willing refrain use vaginal product object include , tampon , female condom , cotton wool , rag , diaphragm , cervical cap ( vaginal barrier method ) , douche , lubricant , vibrators/dildos , dry agent 14 day prior enrollment duration trial ; Willing use oral contraceptive avoid menstruation , necessary , take part trial ; Documentation abnormality Pap test , include grossly bloody smear , within 3 month prior screen ; Willing refrain participation research trial duration trial ; Willing provide adequate locator information trial retention purpose reachable per local standard procedure [ e.g. , home visit telephone ; via family close neighbour contact ( confidentiality maintain ) ] ; Willing agree abstain oral contact genitalia gel use period , well total 3 day ( 72 hour ) biopsy procedure : Willing remain sexually abstinent gel use period trial ; Hepatitis B C negative time enrollment . Currently pregnant last pregnancy outcome within 3 month prior screen ; Currently breastfeed ; Currently within two month participation clinical research trial involve investigational market product prior screen ; Untreated symptomatic urogenital infection , e.g. , urinary tract sexually transmitted infection , gynaecological condition vaginal itching , pain , discharge , within 2 week prior enrolment ; Presence abnormal clinically significant physical finding vulva , vaginal wall cervix pelvic examination and/or colposcopy preenrolment ; History urogenital uterine prolapse , undiagnosed vaginal bleeding , urethral obstruction , incontinence urge incontinence ; Current vulvar vaginal symptoms/abnormalities could influence trial result ; Pap test result require cryotherapy , biopsy , treatment ( infection ) ; evaluation [ include finding atypical squamous cell undetermined significance ( ASCUS ) ] ; Symptomatic genital HSV infection history genital herpetic infection ; Any Grade 2 , 3 4 haematology , chemistry urinalysis laboratory abnormality baseline ( screen ) accord DAIDS Table Grading Adverse Events ( NOTE : This table find : http : //rcc.techres.com/safetyandpharmacovigilance ; standardize version provide research centre Study Operations Manual ) ; Unexplained , abnormal bleed per vagina follow vaginal intercourse , gynaecologic surgery within 90 day prior enrollment ; Any history anaphylaxis severe allergy result angioedema ; history sensitivity/allergy latex silicone ; Any serious acute , chronic progressive disease ( e.g. , known history neoplasm , cancer , diabetes , cardiac disease , autoimmune disease , HIV , AIDS , blood dyscrasia ) , sign cardiac disease , renal failure , severe malnutrition ; Have undergone hysterectomy ; History drug abuse within 1 year enrollment ; Any condition ( ) , opinion Investigator , might interfere adherence trial requirement evaluation trial objective .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>